沈杨

沈杨

妇产科学，博士（后）导师

研究方向：

1、妇科肿瘤早期诊断（ctDNA、类器官、蛋白筛选）；

2、妇科肿瘤治疗（缓释药物系统、人工智能药物开发、CAR-T肿瘤疫苗）；

3、腔镜器械研发(Robotic )；

4、盆底疾病（MDT、康复仪器）；

职称：东南大学妇产科学系主任、三级教授、主任医师、University of Arizona Medical Center访问学者、江苏省333工程第二层次人才、江苏省妇幼健康重点人才

职务：东南大学附属中大医院副院长、南京市智慧妇产医学重点实验室负责人

学术任职：江苏省医学会妇产科分会副主任委员，中国临床肿瘤学会（CSCO）妇科肿瘤专业委员会常委，中国抗癌协会宫颈癌整合防筛专委会副主任委员，中国老年保健协会妇科肿瘤专委会主委，中国研究型医院学会病毒肿瘤专委会常委，江苏省研究型医院学会妇科人工智能与微无创专委会主任委员，江苏省妇幼保健研究会女性康复专委会副主任委员

主持课题及经费：承担国家自然科学基金三项，国家重点研发计划子项目一项，江苏省重点研发项目一项，省市级项目7项等

代表性科研成果：获国家妇幼科技进步二等奖一项，中国发明创业创新二等奖一项，江苏省卫健委医学引进新技术二等奖，省妇幼新技术引进一等奖两项和二等奖一项，省预防医学科技进步三等奖一项等；发表论文90余篇。

代表性文章：

1、Yin, H., Hua, Y., Feng, S., Xu, Y., Ding, Y., Liu, S., Chen, D., Du, F., Liang, G., Zhan, W., & Shen, Y*. (2024). In Situ Nanofiber Formation Blocks AXL and GAS6 Binding to Suppress Ovarian Cancer Development. Advanced materials (Deerfield Beach, Fla.), e2308504.

2、Liu, S., Ji, F., Ding, Y., Ding, B., Feng, S., Brennick, C., Lin, H., Zhang, T., & Shen, Y*. (2024). VISTA: A promising target for overcoming immune evasion in gynecologic cancers. International Immunopharmacology, 138.

3、Hua, Y., & Shen, Y*. (2024). Applications of self-assembled peptide hydrogels in anti-tumor therapy. Nanoscale advances, 6(12), 2993–3008.

4、Feng, S., Ding, B., Dai, Z., Yin, H., Ding, Y., Liu, S., Zhang, K., Lin, H., Xiao, Z., & Shen, Y*. (2024). Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter. Journal of translational medicine, 22(1), 280.

5、Zhao, M., Qiu, S., Wu, X., Miao, P., Jiang, Z., Zhu, T., Xu, X., Zhu, Y., Zhang, B., Yuan, D., Zhang, Y., Sun, W., He, A., Zhao, M., Hou, W., Zhang, Y., Shao, Z., Jia, M., Li, M., Chen, J.,…Shen, Y*. (2023). Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China. Targeted oncology, 18(6), 869–883.

6、Ye, Z., Li, S., Mi, X., Shao, B., Dai, Z., Ding, B., Feng, S., Sun, B., Shen, Y*., & Xiao, Z. (2023). STMHCpan, an accurate Star-Transformer-based extensible framework for predicting MHC I allele binding peptides. Briefings in bioinformatics, 24(3), bbad164.

7、Ding, B., Yan, W., Shen, S., Meng, D., Chen, X., Wang, S., & Shen, Y*. (2023). Immune-Related Genes' Prognostic, Therapeutic and Diagnostic Value in Ovarian Cancer Immune-Related Gene Biomarker in Ovarian Cancer. Cancer Control, 30, 10732748231168756

8、Li, Z., Yin, H., Chen, K., Ding, B., Xu, J., Ren, M., Zhang, C., & Shen, Y*. (2022). Effects of bisphenol A on uterine leiomyoma: In vitro and in vivo evaluation with mechanistic insights related to XBP1. Ecotoxicology and environmental safety, 247, 114201.

9、Hu, T., Wu, Z., Sang, W., Ding, B., Chen, K., Li, X., Shen, Y*., & Ni, Z. (2022). A sensitive electrochemical platform integrated with a 3D graphene aerogel for point-of-care testing for tumor markers. Journal of materials chemistry. B, 10(36), 6928–6938.

10、Hua, Y., Yin, H., Liu, X., Xie, J., Zhan, W*., Liang, G*., & Shen, Y*. (2022). Salt‐Inducible Kinase 2‐Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis. Advanced Science, e2202260.

11、Si, W., Yuan, R., Wu, G., Kan, Y., Sha, J., Chen, Y., Zhang, Y., & Shen, Y*. (2022). Navigated Delivery of Peptide to the Nanopore Using In-Plane Heterostructures of MoS2 and SnS2 for Protein Sequencing. The journal of physical chemistry letters, 13(17), 3863–3872.

12、Feng, S., Ge, Y., Ma, X., Zhang, K., Ge, M., Li, L., & Shen, Y*. (2022). The genomic landscape of invasive stratified mucin-producing carcinoma of the uterine cervix: the first description based on whole-exome sequencing. Journal of translational medicine, 20(1), 187.

13、Chen, Y., Wu, C., Wang, C., Zhang, T., Hua, Y., Shen, Y*., & Liang, G. (2021). Bioluminescence Imaging of Urokinase-Type Plasminogen Activator Activity in Vitro and in Tumors. Anal Chem, 93(29), 9970-9973.

14、Liu, T., Di, Q. N., Sun, J. H., Zhao, M., Xu, Q., & Shen, Y*. (2020). Effects of nonylphenol induced oxidative stress on apoptosis and autophagy in rat ovarian granulosa cells. Chemosphere, 261, 127693.